Effect of valproic acid on miRNAs affecting histone deacetylase in a model of anaplastic thyroid cancer
Makaleler > Tam Makale · 2021
Yazarlar: Nur SELVİ GÜNEL, Nihal Birden, Cansu Caliskan Kurt, BAKİYE GÖKER BAĞCA, Behrouz Shademan, Fatma Sogutlu, Neslihan Pınar ÖZATEŞ AY, Çığır BİRAY AVCI
Molecular Biology Reports, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2021, cilt 48, ss 6085-6091
DOI: 10.1007/s11033-021-06616-2
Özet
Background Thyroid cancer is the most common malignant tumor of the endocrine system seen in the thyroid gland. More than 90% of thyroid cancers comprise papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC). Although anaplastic thyroid carcinoma (ATC) accounts for less than 2% of thyroid cancer. But patients' lifespan after diagnosis is about 6 months. Surgical interventions, radioactive iodine use, and chemotherapy are not sufficient in the treatment of ATC, so alternative therapies are needed. Methods and results The WST-1 assay test was performed to evaluate the anti-proliferative effects of Valproic acid (VPA). Also, the effect of VPA on miRNAs affecting histone deacetylase was determined by Quantitative RT-PCR. In the SW1736 cell line, IC50 dose for VPA was found 1.6 mg/ml. In our study, the level of oncogenic genes expression in cells treated with VPA, including miR-184, miR-222-5p, miR-124-3p, and miR-328-3p, decreased. Also, the expression of tumor inhibitory genes including miR-323-5p, miR-182-5p, miR-138-5p, miR-217, miR-15a-5p, miR-29b-3p, miR-324-5p and miR-101-5p increased significantly. Conclusions VPA can ad-just countless gene expression patterns, including microRNAs (miRNAs), by targeting histone deacetylase (HDAC). However, further studies are required for more accurate results.